Priority Lists
Protocol Posting of
Activations
Closures
Evaluation of the Combination of Docetaxel (Taxotere®)/ Carboplatin in Patients with Metastatic or Recurrent Squamous Cell Carcinoma of the Head and Neck (SCCHN), Phase II
| Study Coordinator(s) | Wolfram E. Samlowski, M.D., J. Philip Kuebler, M.D.,Ph.D. |
| Participants | Members, Medical Oncologists, NCORP |
| Closure Date | 2001-01-01 |
Amendments, Revisions, Memoranda
Amendment #2
Phase III Randomized Study of Concurrent Tretinoin and Chemotherapy With or Without Arsenic Trioxide (AS2O3) (NSC #706363) as Initial Consolidation Therapy Followed by Intermittent Tretinoin Maintenance Therapy Versus Observation for Patients with Untreated Acute Promyelocytic Leukemia
| Action Codes | ER |
| Study Coordinator(s) | Steven E. Coutre, M.D., David R. Head, M.D., Cheryl L. Willman, M.D., Marilyn L. Slovak, Ph.D. |
| Participants | Pathologists, NCORP, Members |
Docetaxel Memorandum
A Phase III Study of Doxorubicin-Cyclophosphamide Therapy Followed by Paciltaxel or Docetaxel Given Weekly or Every 3 Weeks in Patients with Axillary Node-Positive or High-Risk Node Negative Breast Cancer
| Study Coordinator(s) | Silvana Martino, D.O. |
| Participants | Members, Medical Oncologists, Pathologists, NCORP, Surgeons |
Memorandum
Phase III Study of Paclitaxel Versus Liposomal Doxorubicin for the Treatment of Advanced AIDS-Associated Kaposi’s Sarcoma
| Study Coordinator(s) | Lode J. Swinnen, M.D. |
| Participants | Members, Medical Oncologists, NCORP |
Docetaxel Memorandum
Phase III Study of Adriamycin/Taxotere vs. Adriamycin/Cytoxan for the Adjuvant Treatment of Node Positive or High Risk Node Negative Breast Cancer
| Study Coordinator(s) | Silvana Martino, D.O. |
Memorandum
A Phase III Study of Flt3 Ligand (Flt3L) (NSC #696599) Therapy in Acute Myeloid Leukemia (AML) Patients in Remission
| Study Coordinator(s) | John E. Godwin, M.D., David R. Head, M.D., Cheryl L. Willman, M.D., Marilyn L. Slovak, Ph.D. |
| Participants | Members, NCORP |
Revision #3
Phase III Trial of High Dose Interferon Alpha-2b versus Cisplatin, Vinblastine, DTIC Plus IL-2 and Interferon in Patients with High Risk Melanoma
| Study Coordinator(s) | Lawrence E. Flaherty, M.D., John A. Thompson, M.D., Ralph J. Tuthill, M.D., John Vetto, M.D., Vernon K. Sondak, M.D., Jeffrey A. Sosman, M.D. |
| Participants | Members, NCORP, Medical Oncologists, Surgeons, Pathologists, ECOG, COG, US INSTITUTIONS ONLY |
Revision #2
Evaluation of CHOP Plus Rituximab Plus Involved Field Radiotherapy for Stages I, IE, and Non-Bulky Stages II and IIE, CD20 Positive, High Risk Localized Aggressive Histologies of Non-Hodgkin’s Lymphoma, Phase II
| Study Coordinator(s) | Thomas P. Miller, M.D., B. Dino Stea, M.D.,Ph.D., Catherine P. Leith, M.D. |
| Participants | Members, Medical Oncologists, Pathologists, NCORP |
Docetaxel Memorandum
Docetaxel and Estramustine Versus Mitoxantrone and Prednisone for Advanced, Hormone Refractory Prostate Cancer, Phase III.
| Study Coordinator(s) | Daniel P. Petrylak, M.D., Jeffrey A. Jones, M.D., Maha H.A. Hussain, M.D., Donna L. Berry, R.N.,Ph.D. |
| Participants | UCOP, Medical Oncologists, Surgeons, CALGB, NCCTG, EPP, NCORP, Members, CTSU |
Revision #7
Induction Chemotherapy Followed by Chemoradiation for Organ Preservation in Patients with Advanced Resectable Cancer of the Hypopharynx and Base of Tongue, Phase II
| Study Coordinator(s) | S.G. Urba, M.D., Steven C. Marks, M.D., P.G. Shankar Giri, M.D., David J. Adelstein, M.D. |
- IP - Pts Must Be Informed
- AC - Consent Must Be Amended
- CBR - No Registration Allowed until IRB Review
- RC - Formal Re-consent Required
- FBR - Full Board Review Required
- ER - Expedited Review Acceptable
- NR - No IRB Review Required